Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05710146 Withdrawn - Blood Loss Clinical Trials

Tranexamic Acid (TXA) in Hip Arthroscopy

Start date: December 2023
Phase: Phase 3
Study type: Interventional

The primary goal of this study will be to determine if perioperative IV Tranexamic Acid (TXA) administration will reduce intra-operative bleeding and subsequently improve visual clarity during surgery and reduce operative traction time in patients undergoing hip arthroscopy. Additionally, this study aims to determine whether IV TXA injections will reduce post-operative pain and affect hip-specific patient-reported outcomes in patients undergoing hip arthroscopy.

NCT ID: NCT05672407 Withdrawn - Hemorrhage Clinical Trials

The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery

Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

This study investigates the effect of tranexamic acid, a medication that helps reduce bleeding, in patients undergoing surgeries around their eyes.

NCT ID: NCT05583539 Withdrawn - Cirrhosis, Liver Clinical Trials

Thromboelastography Guided Blood Product Transfusion for Upper Gastrointestinal Bleeding in Cirrhosis

STRATEGIC
Start date: January 16, 2025
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare resuscitation strategies in patients with cirrhosis and gastrointestinal bleeding. The main question it aims to answer is whether thromboelastography guided resuscitation decreased the amount of fresh frozen plasma patients receive. Patients will receive blood products guided by thromboelastography in the intervention group. Researchers will compare the patients who undergo thromboelastography guided resuscitation to those who receive usual care to see which strategy leads to the use of less blood products, specifically less fresh frozen plasma.

NCT ID: NCT05518279 Withdrawn - Hip Fractures Clinical Trials

Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures

Start date: September 2019
Phase: Phase 3
Study type: Interventional

The study is a prospective, randomized, double blinded, placebo controlled trial that aims to investigate the hypothesis that early administration of tranexamic acid (TXA) following diagnosis of hip fracture will lower pre and postoperative blood loss and transfusion rates. Patients who present to the hospital with a hip fracture will be recruited and randomized into two treatment arms. The treatment group will receive 1950mg of oral TXA (three tablets, 650 mg each) and the control group will be given three tablets of oral placebo while in the Emergency Department. Patients will then be admitted to the Orthopaedic Trauma service and treated surgically with cephalomedullary nail, hemiarthroplasty, sliding hip screw, percutaneous screws, or total hip arthroplasty.

NCT ID: NCT05080881 Withdrawn - Blood Loss Clinical Trials

Noninvasive Monitor of Vascular Volume Fluid Shifts

Start date: December 15, 2021
Phase: N/A
Study type: Interventional

Blood volume measurements are a critical step in the emergency care of trauma patients. The typical approach to this is to rely on historical information, physical examination and metrics such as heart rate. There is currently no good real-time measure to track blood volume. This study investigates the use of phonocardiography (listening to the sounds made by the heart) to track changes in central blood volume.

NCT ID: NCT05075486 Withdrawn - Mortality Clinical Trials

Quality Improvement to Reduce Mortality or Severe Intracranial Hemorrhage in Neonatal Extracorporeal Life Support

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a three-year pre- and post- interventional study to assess the effectiveness of collaborative quality improvement interventions on reducing mortality and severe intracranial hemorrhage (ICH) for neonates receiving extracorporeal life support (ECLS) in China.

NCT ID: NCT05032118 Withdrawn - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Pilot Study of Ketamine Sedation for Aneurysmal Subarachnoid Hemorrhage

PENDULUM
Start date: April 27, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Aneurysmal subarachnoid hemorrhage (aSAH) is bleeding into the space between the brain and the tissues that surround the brain as a result of a ruptured aneurysm and is a type of stroke associated with high morbidity and mortality. Those that survive the initial bleed are critically ill and require prolonged intensive care unit stays since they are at risk for a multitude of secondary insults that can further worsen functional outcomes. An especially feared secondary insult is delayed cerebral ischemia (DCI), which is a lack of blood flow to a particular portion of the brain that can result in an ischemic stroke and produce profound neurologic deficits. How DCI develops in some people after aSAH and not others is unknown, but many have hypothesized various mechanisms such as 1) cerebral vasospasm, a focal anatomic narrowing of the blood vessels in the brain that could decrease downstream blood flow, 2) abnormal electrical activity, and 3) microthrombi, or the formation of small blood clots. It is vitally important to identify a therapy that could protect the brain from these secondary insults that happen days after the initial brain bleed. Ketamine is a drug used in the majority of hospitals around the world for various indications, including general anesthesia, sedation, and for pain. Ketamine blocks a specific receptor that is present within the brain and in doing so could play a critical protective role against these secondary insults after aSAH by blocking the flow of dangerous chemicals. Ketamine may provide the following beneficial properties after aSAH: 1) pain control, 2) seizure prevention, 3) blood pressure support, 4) dilation of the brain blood vessels, 5) sedation, 6) anti-depressant, and 7) anti-inflammatory. This project is designed to test whether ketamine sedation in the intensive care unit after aneurysm repair provides better outcomes than the currently used sedation regimen.

NCT ID: NCT04933240 Withdrawn - Vaginal Bleeding Clinical Trials

Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial

Start date: May 2022
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to evaluate the ability of medicines called tamoxifen or estradiol to prevent annoying vaginal bleeding for arm implant users.

NCT ID: NCT04890379 Withdrawn - Clinical trials for Intracerebral Hemorrhage

Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH.

NCT ID: NCT04863339 Withdrawn - Surgery Clinical Trials

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

Start date: March 2022
Phase: Phase 2
Study type: Interventional

This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compared to a placebo. To answer this hypothesis, the investigators are conducting a randomized controlled trial in which half of participants will receive TXA and half will receive placebo (saline) in a double blind fashion.